- 40 efficiency equal too or just under other leading treatments is not an anomaly, achieved in phase 1 and phase 2 across both trials with excellent safety profile - the vehicle driven result is the anomaly - 40 is good enough for first product of the line and we have a long list of products in the pipeline, even if the efficiency comes in equal too all other competitors we will have multiple products with superior safety profiles in which other companies have spent many of millions on to have far less products - /
- 40 efficiency equal too or just under other leading treatments...
-
- There are more pages in this discussion • 11,356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.010(2.67%) |
Mkt cap ! $696.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $826.1K | 2.160M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77136 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 635449 | 14 |
View Market Depth
| Last trade - 11.30am 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |